Literature DB >> 30624571

Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid.

Khalaf Kridin1,2, Reuven Bergman1,3.   

Abstract

Importance: The prevalence of mucosal involvement in bullous pemphigoid (BP) is inconsistent. Nonoral mucosal involvement was reported anecdotally in few patients with BP. Objective: To evaluate the prevalence of mucosal involvement in patients with BP, and to characterize the subgroup of patients with mucosal lesions. Design, Setting, and Participants: A retrospective cohort study was performed including 328 consecutive patients diagnosed with immunopathologically validated BP at a tertiary care referral center for autoimmune bullous diseases in northern Israel between January 1, 2000, and December 31, 2017. Main Outcome and Measures: The study was conducted to estimate the prevalence and distribution of mucosal involvement among patients with BP. Patients with mucosal involvement were compared with the remaining BP patients regarding clinical and immunological features, laboratory analyses, and treatments.
Results: The study cohort included 139 (42.4%) male and 189 (57.6%) female patients, with a mean (SD) age of 78.0 (11.8) years at presentation. Fifty-six patients (17.1%) presented with mucosal lesions. The oral mucosa was the most frequently affected mucosal surface (n = 44; 13.7%), followed by the laryngeal (n = 16; 4.9%) and the genital (n = 10; 3.0%) mucosae. Among patients with oral lesions, the most involved oral structures were the buccal mucosa (n = 25; 55.6%) and the soft palate (n = 24; 53.3%). Compared with other patients with BP, patients with mucosal involvement were younger (71.8 [14.4] years vs 79.3 [10.8] years; P < .001), presented more frequently with extensive disease (55.4% vs 39.7%; P = .002), had less peripheral eosinophilia (17.8% vs 41.9%; P < .001), and were treated with higher doses of corticosteroids (prednisone >1 mg/kg: 67.9% vs 51.8%; P = .03). Conclusions and Relevance: Mucosal lesions are present in a notable subgroup of patients with BP and are associated with disease severity. Laryngeal involvement is more common than previously appreciated.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30624571      PMCID: PMC6439539          DOI: 10.1001/jamadermatol.2018.5049

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  32 in total

1.  Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort.

Authors:  R della Torre; C Combescure; B Cortés; G Marazza; H Beltraminelli; L Naldi; L Borradori
Journal:  Br J Dermatol       Date:  2012-11       Impact factor: 9.302

2.  Mortality of patients with bullous pemphigoid in Korea.

Authors:  Ji Hye Lee; Soo-Chan Kim
Journal:  J Am Acad Dermatol       Date:  2014-06-12       Impact factor: 11.527

3.  Usefulness of a Simple Immunohistochemical Staining Technique to Differentiate Anti-p200 Pemphigoid From Other Autoimmune Blistering Diseases: A Report of 2 Cases.

Authors:  I García-Díez; M E Martínez-Escala; N Ishii; T Hashimoto; J M Mascaró Galy; R M Pujol; J E Herrero-González
Journal:  Actas Dermosifiliogr       Date:  2016-04-16

4.  Usefulness of collagen IV immunostaining for diagnosis of canine epidermolysis bullosa acquisita.

Authors:  T Olivry; S M Dunston
Journal:  Vet Pathol       Date:  2010-04-07       Impact factor: 2.221

5.  Childhood vulval pemphigoid: a clinical and immunopathological study of five patients.

Authors:  A M Farrell; G Kirtschig; K L Dalziel; J Allen; G Dootson; S Edwards; F Wojnarowska
Journal:  Br J Dermatol       Date:  1999-02       Impact factor: 9.302

6.  BP230- and BP180-specific auto-antibodies in bullous pemphigoid.

Authors:  Sybille Thoma-Uszynski; Wolfgang Uter; Susanne Schwietzke; Silke C Hofmann; Thomas Hunziker; Philippe Bernard; Regina Treudler; Christos C Zouboulis; Gerold Schuler; Luca Borradori; Michael Hertl
Journal:  J Invest Dermatol       Date:  2004-06       Impact factor: 8.551

Review 7.  Nonbullous pemphigoid: prodrome of bullous pemphigoid or a distinct pemphigoid variant?

Authors:  R Strohal; K Rappersberger; H Pehamberger; K Wolff
Journal:  J Am Acad Dermatol       Date:  1993-08       Impact factor: 11.527

8.  Airway management in a patient with bullous pemphigoid.

Authors:  Mohammad Yasir; Fauzia Anis Khan
Journal:  J Coll Physicians Surg Pak       Date:  2013-08       Impact factor: 0.711

9.  Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.

Authors:  Chika Chijiwa; Shintaro Takeoka; Masahiro Kamata; Mihoko Tateishi; Saki Fukaya; Kotaro Hayashi; Atsuko Fukuyasu; Takamitsu Tanaka; Takeko Ishikawa; Takamitsu Ohnishi; Shinichi Watanabe; Yayoi Tada
Journal:  J Dermatol       Date:  2018-02-06       Impact factor: 4.005

10.  Accessible Diagnostic Methods to Differentiate between Epidermolysis Bullosa Acquisita and Other Subepidermal Autoimmune Bullous Diseases.

Authors:  Khalaf Kridin
Journal:  Indian J Dermatol       Date:  2018 Sep-Oct       Impact factor: 1.494

View more
  13 in total

1.  Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.

Authors:  Ágnes Kinyó; Anita Hanyecz; Zsuzsanna Lengyel; Dalma Várszegi; Péter Oláh; Csaba Gyömörei; Endre Kálmán; Tímea Berki; Rolland Gyulai
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

2.  Nonbullous pemphigoid secondary to PD-1 inhibition.

Authors:  Sean Singer; Caroline A Nelson; Christian G Lian; Anna K Dewan; Nicole R LeBoeuf
Journal:  JAAD Case Rep       Date:  2019-10-03

3.  Case Report: Variety of Target Antigens During 1 Year Follow-Up of a Patient Initially Diagnosed With Bullous Pemphigoid.

Authors:  Hua Qian; Zhijun Zhou; Luhuai Shi; Huicheng Li; Weijun Liu; Yong Ai; Yangmin Gao; Suying Feng; Takashi Hashimoto; Xiaoguang Li
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

4.  Prognostic factors for mortality in bullous pemphigoid: A systematic review and meta-analysis.

Authors:  Xianxia Chen; Yaqiang Zhang; Zhicheng Luo; Yujuan Wu; Taoxiang Niu; Jiayuan Zheng; Yuanyuan Xie
Journal:  PLoS One       Date:  2022-04-15       Impact factor: 3.752

Review 5.  Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review.

Authors:  Xinyi Chen; Wenlin Zhao; Hongzhong Jin; Li Li
Journal:  Front Med (Lausanne)       Date:  2021-05-20

6.  A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder.

Authors:  Xiaoxiao Wang; Mariano Suppa; Pascal Bruderer; Nicolas Sirtaine; Sandrine Aspeslagh; Joseph Kerger
Journal:  Case Rep Oncol       Date:  2021-06-15

Review 7.  Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.

Authors:  Nina van Beek; Detlef Zillikens; Enno Schmidt
Journal:  Dtsch Arztebl Int       Date:  2021-06-18       Impact factor: 8.251

8.  Assessment of the Characteristics and Associated Factors of Infectious Complications in Bullous Pemphigoid.

Authors:  Jia Chen; Xuming Mao; Wenling Zhao; Bingjie Zhang; Xinyi Chen; Chenyang Yu; Zehui Zheng; Hongzhong Jin; Li Li
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

9.  Bullous pemphigoid associated with nintedanib.

Authors:  Amelia M Hasson; Gregory Cheeney; Lawrence A Ho; Jay C Vary
Journal:  JAAD Case Rep       Date:  2019-08-30

10.  More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.

Authors:  Ralf J Ludwig; Khalaf Kridin; Sascha Ständer; Enno Schmidt; Detlef Zillikens
Journal:  Am J Clin Dermatol       Date:  2021-01       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.